- The impact of high frequency rapid viral antigen screening on COVID-19 spread and
 outcomes: a validation and modeling study

4	Authors: Beatrice Nash ^{1,2*} , Anthony Badea ^{1,3*} , Ankita Reddy ^{1,4*} , Miguel Bosch ^{1,5} , Nol Salcedo ¹ ,
5	Adam R. Gomez ¹ , Alice Versiani ⁶ , Gislaine Celestino Dutra Silva ⁶ , Thayza Maria Izabel Lopes
6	dos Santos ⁶ , Bruno H. G. A. Milhim ⁶ , Marilia M Moraes ⁶ , Guilherme Rodrigues Fernandes
7	Campos ⁶ , Flávia Quieroz ⁶ , Andreia Francesli Negri Reis ⁶ , Mauricio L. Nogueira ⁶ , Elena N.
8	Naumova ⁷ , Irene Bosch ^{1,8} , Bobby Brooke Herrera ^{1,9†}
9	
10	*These authors contributed equally to this work.
11	
12	Affiliations:
13	¹ E25Bio, Inc., Cambridge, MA, USA
14	² Department of Computer Science, Harvard University School of Engineering and Applied
15	Sciences, Cambridge, MA, USA
16	³ Department of Physics, Harvard University, Cambridge, MA, USA
17	⁴ Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
18	⁵ InfoGeosciences LLC, Houston, TX, USA
19	⁶ Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, Brazil
20	⁷ Division of the Nutrition Epidemiology and Data Science, Friedman School of Nutrition Science
21	and Policy, Tufts University, Boston, MA, USA
22	⁸ Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA

23	⁹ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health,
24	Boston, MA, USA
25	
26	[†] Corresponding Author. BBH, email: <u>bbherrera@e25bio.com</u>
27	
28	Short Title: Modeling rapid antigen testing on COVID-19 spread
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	

46 Abstract

High frequency screening of populations has been proposed as a strategy in facilitating control of the COVID-19 pandemic. Here we use computational modeling, coupled with clinical data from rapid antigen tests, to predict the impact of frequent rapid testing on COVID-19 spread and outcomes. Using patient nasal or nasopharyngeal swab specimens, we demonstrate that the sensitivity/specificity of two rapid antigen tests compared to quantitative real-time polymerase chain reaction (qRT-PCR) are 80.0%/91.1% and 84.7%/85.7%, respectively; moreover, sensitivity correlates directly with viral load. Based on COVID-19 data from three regions in the United States and São José do Rio Preto, Brazil, we show that high frequency, strategic population-wide rapid testing, even at varied accuracy levels, diminishes COVID-19 infections, hospitalizations, and deaths at a fraction of the cost of nucleic acid detection via gRT-PCR. We propose large-scale antigen-based surveillance as a viable strategy to control SARS-CoV-2 spread and to enable societal re-opening.

69 INTRODUCTION

70 The COVID-19 pandemic has taken an unprecedented toll on lives, wellbeing, healthcare 71 systems, and global economies. As of 4 November 2020, there have been more than 47.6 million 72 confirmed cases globally with more than 1 million confirmed deaths (1). However, these numbers 73 and the current mapping of disease spread present an incomplete picture of the outbreak largely 74 due to the lack of adequate testing, particularly as undetected infected cases are the main source 75 of disease spread (2-7). It is estimated that the reported detection rate of actual COVID-19 cases is only 1-2% (5). As of November 2020, the United States, Brazil, and India remain the top three 76 77 countries with the highest number of COVID-19 cases and deaths worldwide. As countries begin 78 to re-open their economies, a method for accessible and frequent surveillance of COVID-19, with 79 the necessary rapid quarantine measures, is crucial to prevent the multiple resurgences of the disease. 80

The current standard of care rightfully places a strong focus on the diagnostic limit of 81 82 detection, yet frequently at the expense of both cost and turnaround time. This situation has 83 contributed to limited population testing largely due to a dearth of diagnostic resources. 84 Quantitative real-time polymerase chain reaction (qRT-PCR) is the gold-standard method for 85 clinical diagnosis, with high sensitivity and specificity, but these tests are accompanied by the need 86 for trained personnel, expensive reagents and instrumentation, and a significant amount of time to 87 execute. Facilities offering qRT-PCR sometimes require a week or longer to complete and return 88 the results to the patient. During this waiting period the undiagnosed individual may spread the 89 infection and/or receive delayed medical treatment. Moreover, due to the cost and relative 90 inaccessibility of qRT-PCR in both resource-limited and abundant settings, large-scale screening 91 using qRT-PCR at frequent intervals remains impractical to identify infected but asymptomatic or mildly symptomatic infections. Numerous studies have reported asymptomatic COVID-19 cases
as well as a variation in viral load within and between individuals at different time points,
suggesting the need for more frequent testing for informative surveillance.

95 Technologies alternate to qRT-PCR, such as rapid viral antigen detection, clustered 96 regularly interspaced short palindromic repeats (CRISPR), and loop-mediated isothermal 97 amplification (LAMP) of SARS-CoV-2 provide potential large-scale screening applications, yet their implementation is stymied by requirements for qRT-PCR-like accuracy before they can reach 98 the market (8). In countries such as India, where the qRT-PCR resources would not be sufficient 99 100 to cover monitoring of the population, the use of rapid antigen tests is well underway (9, 10). In 101 early May 2020, the United States Food and Drug Administration (FDA) authorized the first 102 antigen test for the laboratory detection of COVID-19, citing a need for testing beyond molecular 103 and serological methods. Antigen testing detects the viral proteins rather than nucleic acids or 104 human antibodies, allowing for detection of an active infection with relative ease of sample 105 collection and assay. These rapid assays – like other commercially-available rapid antigen tests -106 can be mass-produced at low prices and be administered by the average person without a laboratory 107 or instrumentation. These tests also take as little as 15 minutes to determine the result, enabling 108 real-time surveillance and/or diagnosis. Although antigen tests usually perform with high 109 specificities (true negative rate), their sensitivity (true positive rate) is often lower when compared to molecular assays. While qRT-PCR can reach a limit of detection as low as 10² genome copies 110 111 per mL, rapid antigen testing detects viral protein that is assumed to correlate with approximately 112 10^5 genome copies per mL (11).

We hypothesize that frequent antigen-based rapid testing even with lower sensitivities
compared to qRT-PCR - along with appropriate quarantine measures - can be more effective at

115 decreasing COVID-19 spread than less frequent molecular testing of symptomatic individuals. 116 Keeping in mind the realities of daily testing in resource-limited regions, we also hypothesize that 117 testing frequency can be adjusted according to the prevalence of the disease; that is, an uptick in 118 reported cases should be accompanied by more frequent testing. During the viral incubation period, 119 high infectivity correlates with a high viral load that can be detected by either qRT-PCR or rapid 120 antigen testing (12-16). Rapid tests thus optimize diagnosis for the most infectious individuals. 121 Studies also point to the relatively small window of time during an individual's incubation period 122 in which the qRT-PCR assay is more sensitive than rapid tests (12).

123 In this study we report the clinical validation of two direct antigen rapid tests for detection 124 of SARS-CoV-2 spike glycoprotein (S) or nucleocapsid protein (N) using retrospectively collected 125 nasopharyngeal or nasal swab specimens. Using the clinical performance data, we develop a 126 modeling system to evaluate the impact of frequent rapid testing on COVID-19 spread and 127 outcomes using a variation of a SIR model, which has been previously used to model COVID-19 128 transmission (17–23). We build on this model to incorporate quarantine states and testing protocols 129 to examine the effects of different testing regimes. This model distinguishes between undetected 130 and detected infections and separates severe cases, specifically, those requiring hospitalization, 131 from those less so, which is important for disease response systems such as intensive care unit 132 triaging. We simulate COVID-19 spread with rapid testing and model disease outcomes in three 133 regions in the United States and São José do Rio Preto, Brazil - the site of the clinical validation 134 study - using publicly available data. To date, COVID-19 modeling describes the course of disease 135 spread in response to social distancing and quarantine measures, and a previous simulation study 136 has shown that frequent testing with accuracies less than qRT-PCR, coupled with quarantine 137 process and social distancing, are predicted to significantly decrease infections (12, 17, 23-27).

138 This is the first modeling system using publicly-available data to simulate how potential public 139 health strategies based on testing performance, frequency, and geography impact the course of 140 COVID-19 spread and outcomes. Our findings suggest that a rapid test, even with sensitivities 141 lower than molecular tests, when strategically administered 2-3 times per week, will reduce 142 COVID-19 spread, hospitalizations, and deaths at a fraction of the cost of nucleic acid testing via 143 qRT-PCR. Modern surveillance systems should be well equipped with rapid testing tools to ensure 144 that disease tracking and control protocols are effective and well-tailored to national, regional, and 145 community needs.

146

147 **RESULTS**

148 Accuracy of Direct Antigen Rapid Tests Correlate with Viral Load Levels

149 Rapid antigen tests have recently been considered a viable source for first-line screening, although concerns about the accuracy of these tests persist. We clinically validated two different 150 151 direct antigen rapid tests for the detection of either N or S from SARS-CoV-2 in retrospectively 152 collected nasal or nasopharyngeal swab specimens. Of the total number of nasal swab specimens 153 evaluated by qRT-PCR for amplification of SARS-CoV-2 N, S, and ORF1ab genes, 100 tested 154 positive and 90 tested negative (Table 1, Table S1). The overall sensitivity and specificity of the 155 rapid antigen test for detection of SARS-CoV-2 N, evaluated across the nasal swab specimens, 156 was 80.0% and 91.1%, respectively. Of the total number of nasopharyngeal swab specimens 157 evaluated by qRT-PCR for amplification of SARS-CoV-2 N, RNA-dependent RNA polymerase 158 (RdRp), and envelope (E) genes, 72 tested positive and 49 tested negative (Table 2, Table S1). The 159 overall sensitivity and specificity of the rapid antigen test for detection of SARS-CoV-2 S, 160 evaluated across the nasopharyngeal swab specimens was 84.7% and 85.7%, respectively.

Altogether, our data demonstrate that the sensitivity of the rapid antigen tests are positivelycorrelated to the viral load level (Table S1).

163 The Ct value indirectly quantifies the viral RNA copy number related to the viral load of 164 the sample for the specific assay (28, 29). Ct values represent the number of qRT-PCR cycles at 165 which generated fluorescence crosses a threshold during the linear amplification phase; Ct values 166 are therefore inversely related to the viral load. The sensitivity of both rapid antigen tests increases 167 as Ct value decreases (Table S1). Moreover, because the Ct value is a variable unit based upon 168 qPCR protocol and instrumentation, we evaluated sensitivity against the percentile of positive 169 cases conditioned to Ct and found similar results. The sensitivity of the rapid antigen test for 170 detection of SARS-CoV-2 N increased from 80.0% at Ct values <40 to 95.8% at Ct values <20 171 (Figure S1A). Similarly, the sensitivity of the rapid antigen test for detection of SARS-CoV-2 S 172 increased from 84.7% at Ct values <35 to 100.0% at Ct values <15 (Figure S1B). Taken together, the clinical data shows that the rapid antigen test performs with increasing accuracy for individuals 173 174 with a higher viral load, and potentially the most infectious (13-16).

175

176 An Enhanced Epidemiological SIDHRE-Q Model

We propose an enhanced epidemiological modeling system, *SIDHRE-Q*, a variant of the classical SIR model in order to expand our clinical validation study and to understand the effects of using frequent rapid tests such as the rapid antigen test on COVID-19 outbreak dynamics. The changes we make to the basic model to encompass the unique characteristics of the COVID-19 pandemic are similar to those presented by Giordano et al. *(16)* (Figure 1, Figure S2). The differential equations governing the evolution of the *SIDHRE-Q* model and descriptions of the parameter values are provided in the material and methods section (Equation 2, Table 3). An individual that begins in **S** may either transition to a Quarantine Uninfected (**Q**-**U**) state via a false positive result or to an Infected Undetected (**I**) state via interaction with an infected individual. Should an individual in **S** move into **Q**-**U**, they are quarantined for 14 days before returning to **S**, a time period chosen based on current knowledge of the infectious period of the disease. One could also conceive of an effective strategy in which individuals exit quarantine after producing a certain number of negative rapid tests in the days following their initial positive result or confirm their negative result using qRT-PCR.

Given that those diagnosed are predominantly quarantined, individuals in I interact more with the S population than do those in Infected Detected (D). Therefore, the infectious rate for I is assumed to be significantly larger than for D. Furthermore, a region's ability to control an outbreak is directly related to how quickly and effectively people in I test into D, reducing their infectiousness through quarantine. This study, in particular, highlights the critical role frequency of testing, along with strict quarantine, has in mitigating the spread of the disease and provides specific testing strategies based on rapid tests we predict to be highly effective.

198 In this model, we assume that individuals receive a positive diagnosis before developing 199 severe symptoms and that those with symptoms severe enough to be potentially fatal will go to the 200 hospital. If an individual develops symptoms, we assume they are tested daily until receiving a 201 positive result; hence, before severe symptoms develop, they will be diagnosed with high 202 probability. Those who do not develop symptoms are tested according to the frequency of tests 203 administered to the general population. Therefore, there is no modeled connection between I and 204 H or between I and E. Removing these assumptions would have negligible impact on the results 205 as these flows are very small.

206 Should an individual test positive and transition to **D**, they may either develop serious 207 symptoms requiring care or recover. Those who develop serious symptoms and transition to state 208 H will then transition to either R or E. The recovered population is inevitably tested, as infected 209 individuals may recover without being detected. Therefore, the Quarantined Recovered (Q-R) 210 state is introduced with the same connections to **R** as the connections between **S** and **Q**-U. Though 211 the reinfection rate of SARS-CoV-2 has been a point of recent debate, it is assumed that the number 212 of re-infected individuals is small (30-34). Therefore, individuals cannot transition from **R** to **S**, 213 hence the separately categorized quarantined populations.

We considered several variations and extensions of the *SIDHRE-Q* model. In simulations, we tested additional states, such as those in the *SIDARTHE* model, which include distinctions between symptomatic and asymptomatic cases for both detected and undetected populations (*17*). Incorporating information about the correlations between viral load and infectivity and sensitivity were also considered. Altogether, our modeling system has been well tuned to predict the impact of high frequency rapid testing on COVID-19 spread and outcomes.

220

Frequent Rapid Testing with Actionable Quarantining Dramatically Reduces DiseaseSpread

In order to demonstrate how strategies could affect the disease spread in different geographies and demographics, we used surveillance data obtained from regions of varying characteristics: the state of Massachusetts (MA), New York City (NYC), Los Angeles (LA), and São José do Rio Preto (SJRP), Brazil, the site of the rapid antigen test clinical validation study. These regions are also selected in our study due to the readily available surveillance data provided by the local governments. We fit the model to the data from each region starting 1 April 2020. At this time point the disease reportedly is most advanced in NYC and least advanced in SJRP, Brazil
with estimated cumulative infection rates of 7.11% and 0.12%, respectively.

After calibrating the *SIDHRE-Q* model, the disease spread is observed with varying validated rapid antigen test performances and frequencies (Figure 2A). Sensitivity (the ratio of true positives to the total number of positives) and specificity (the ratio of true negatives to the total number of negatives) compared to gold-standard qRT-PCR were used as measures of test accuracy.

The rapid test frequency is varied while maintaining an accuracy of 80% sensitivity and 90% specificity, comparable to our clinical data collected in SJRP, Brazil. These testing scenarios are then compared to symptomatic testing, in which individuals receive a rapid test only when presenting symptoms, via either a rapid test or qRT-PCR. Since the primary testing regiment deployed in MA, LA, NYC and SJRP, Brazil is qRT-PCR-based and focused on symptomatic individuals, the symptomatic testing protocol via qRT-PCR is directly estimated from the data to be the rate ν (Table 3).

The difference between the qRT-PCR and rapid test simulations (red and orange lines, respectively) is therefore only sensitivity of testing (Figure 2A). We assumed that test outcome probability is a function only of whether an individual is infected and independent of other factors; one can consider this a lower bound on effectiveness of a strategy, as sensitivity and infectivity are often positively correlated with antigen testing.

To better understand the effect of rapid testing frequency and performance on healthcare capacity and mortality rates, we simulate the testing strategy with 30%-90% sensitivity each with 80% or 90% specificity against the symptomatic testing strategy (Figure S3).

251 As per our hypothesis, frequency and symptom-based testing dramatically reduced 252 infections, simultaneous hospitalizations, and total deaths when compared to the purely symptom-253 based testing regiments, and infections, hospitalization, and death were reduced as frequency 254 increased. Although testing every day was clearly most effective, even testing every fourteen days 255 with an imperfect test gave an improvement over symptomatic testing with qRT-PCR. While the 256 strategy works best when implemented at the very beginning of an outbreak, as demonstrated by 257 the results in SJRP, Brazil, it also works to curb an outbreak that is already large, as demonstrated 258 by the results in NYC. The difference between frequencies is more noticeable when the testing 259 strategy is applied to the outbreak in NYC, leading us to hypothesize that smaller outbreaks require 260 a lower testing frequency than larger ones; note the difference between the dependence on 261 frequency to curb a small initial outbreak in SJRP, Brazil versus a large one in NYC (Figure 2B). 262 For test performance of 80% sensitivity and 90% specificity, the percent of the population 263 that has been infected in total from the beginning of the outbreak to mid-July drops from 18%

(MA), 11% (LA), 26% (NYC), and 11% (SJRP, Brazil) to 3%, 2%, 12%, and 0.26%, respectively,
using a weekly rapid testing and quarantine strategy (with regards to predictions of overall
infection rates, other studies based on seroprevalence and epidemiological predictions have
reached similar conclusions (*35*, *36*)). If testing is increased to once every three days, these
numbers drop further to 1.6% (MA), 1.4% (LA), 9.4% (NYC), and 0.19% (SJRP, Brazil) (Table
S2).

To further examine the relationship between frequency and sensitivity, we modeled the maximum number of individuals in a given state over the 105-day time period for four geographic regions (Figure 2B, Figure S4). In all four geographic regions, as frequency of testing increases, the total infections, maximum simultaneous hospitalizations, and total deaths converge to small 274 percentages regardless of the sensitivity at high frequencies. It is clear that the difference in 275 frequency required to achieve the same result using tests of differing sensitivities is very small. 276 For example, we predict that for the outbreak in LA, a testing strategy started on 1 April of every 277 10 days using a test of sensitivity 90% would have resulted in 2.5% of the population having been 278 infected, while using a test of sensitivity 30% would require a strategy of every 5 days to achieve 279 the same number. Thus, we conclude that frequency is more important than sensitivity in curbing 280 the spread, and a large range of sensitivities prove effective when testing sufficiently often (Figure 281 S4). How frequently, exactly, depends on the specific outbreak and what stage it is in, which leads 282 us to the location-based deployment strategy discussed in a later section. Frequency of testing can 283 be significantly reduced to effectively contain the disease once the initial outbreak has been 284 controlled; it is clear that this takes only a matter of weeks (Figure 2A).

285 On the other hand, according to the specificity of the rapid test and the quarantine duration, larger testing frequency result in a larger percent of the population quarantined (Figure 2A). 286 287 Assuming a 90% rapid test specificity and 14-day quarantine duration, for the 1-, 3- and 7-day 288 frequencies almost 60%, 38% and 20% of the population, respectively, would be guarantined. This 289 figure may be reduced with additional rules for exiting quarantine early, such as after 290 complementary testing. An example of such a strategy is that individuals who test positive are 291 required to either quarantine for two weeks or produce two consecutive negative rapid tests in the 292 two days following their positive result. Assuming 80% sensitivity and 90% specificity, those 293 individuals will reenter the public while still infected with probability 0.04. If uninfected, that 294 individual will exit quarantine after two days with probability 0.81. However, a compromise 295 between the reduction of infections and the proportion of the population in quarantine would be 296 part of the planning for the appropriate testing protocol in each community or region.

Additionally, while high frequency may be necessary to contain a large outbreak initially, relatively infrequent testing, such as every one or two weeks, is sufficient to keep controlled outbreaks small, while reducing the number of quarantined individuals to less than 10% of the population using a two-week mandatory quarantine.

301

A County-Based Testing Strategy Offers a Cost-effective Approach to Large-scale COVID 19 Surveillance

304 To examine the effects of resource-strategic testing schemes, we modeled the COVID-19 305 prevalence by varying testing frequency across counties of California. For this analysis, only 306 California was analyzed because of the accessibility of the county level data and the variability of 307 spread dynamics of the outbreaks between counties. In this scheme, the percent of active infected 308 detected individuals in a county determines the frequency of testing. We define thresholds for the 309 number of active detected infections that, when hit, initiate testing protocols of different 310 frequencies depending on the threshold hit. We first tested evenly spaced thresholds for the number 311 of detected active infections up to 1% of the population, but later adopted thresholds that were 312 determined according to Equation 1. In Equation 1, D = population of state **D** at the time of testing. 313 T = number of active infections which, if reached, initiates everyday testing. The days between 314 tests are rounded to the closest integer value.

315

Days between tests = max
$$(1, 2\log_2(T/D) + 1)$$

316

The days between tests are chosen such that the detected active infections should remain near to or below *T*. If the initial detected active infections are greater than *T*, then the testing frequency of 1 will cause infections to rapidly drop. Both the threshold at which everyday testing begins and

320 the coefficient of log_2T/D can be modified to produce a strategy that is more or less frequent in 321 testing or resource effective; a range of days between tests from 14 days to 1 day are used (Figure 322 3A). The purpose of this strategy is to tailor testing based on the specific characteristics of local 323 outbreaks in order to mitigate the overall spread faster and more efficiently. A scan over different 324 choices of T is shown in Figure 3B; the threshold we choose in Figure 3A is 0.05% because it is 325 successful in curbing the outbreak within the time period we consider. While the choices work for 326 the epidemic in California at the point we start our simulations, 10 April, they do not necessarily 327 reflect the most resource effective choices everywhere. Our analysis could be redone to select the 328 best fine-grained strategy in other states or metropolitan areas.

329 Using a rapid test with a sensitivity of 80% and specificity of 90%, the county-based testing 330 with threshold 0.05% reduces the active infections from 0.94% to 0.0005%, while the uniform 331 strategy with tests administered every 7 days results in double the number of active infections 332 (Figure 3A). As the threshold is reduced, the total cost increases while the cumulative infections, 333 maximum percentage hospitalized, and cumulative deaths all decrease (Figure 3B). Appropriate 334 choice of threshold is dependent on the severity of outbreaks in a specific region and available 335 resources, both logistically and fiscally. With regional data, such as that from California used to 336 produce Figure 3B, this study can be reproduced to calculate an efficient testing strategy that will 337 effectively curb outbreaks of differing severities in any geographic entity.

338 Strategy B in Figure 3 consists of qRT-PCR testing uniformly applied to the highlighted 339 population with a frequency of once weekly. The average cost per person per day is just under \$15. 340 Despite this frequency and the accuracy of qRT-PCR, the strategy does not succeed in curbing the 341 spread as fast as strategy A, which uses a testing sensitivity and specificity of 80% and 90%, 342 respectively, and testing frequency that vary between counties depending on the proportion of their population that is currently infected. The total cost for strategy A is estimated at a fraction of theother at \$1.53 per person per day.

345

346 **DISCUSSION**

347 In this study we examine the potential effects of a novel testing strategy to limit the spread 348 of SARS-CoV-2 utilizing rapid antigen test screening approaches. Our clinical data and SIDHRE-349 Q modeling system demonstrate that 1) frequent rapid testing even at a range of accuracies is 350 effective at reducing COVID-19 spread, 2) rapid antigen tests are a viable source for this strategy 351 and diagnose the most infectious individuals, and 3) strategic geographic-based testing can 352 optimize disease control with the amount of available resources. The information from a diagnostic 353 test itself is of tremendous value, as it can prompt the necessary guarantine measures to prevent 354 spread, guide proper care and triage, and provide crucial disease-tracking information. Diagnostic 355 testing in the United States and abroad, however, has been a significant public health hurdle. The 356 public has witnessed and experienced symptomatic individuals being denied testing due to 357 shortages, and few testing structures for asymptomatic or mildly symptomatic individuals – a 358 significant source of disease spread. Though several factors contributed to the stymied early 359 response measures, such as lockdown and quarantine protocols and adherence, severe testing 360 bottlenecks were a significant culprit (37-39). Early control measures have been shown to decrease 361 lives lost by several orders of magnitude (40). These challenges, though exacerbated during the 362 early months of the pandemic, remain at the forefront of the public health crises.

Diagnosis of SARS-CoV-2 infection by qRT-PCR is the current standard of care, yet remains expensive and requires a laboratory and experienced personnel for sample preparations and experimentation. Significantly, the turnaround time for results can be up to 10 days (*41*). On an individual scale, this leaves the public in limbo, preventing people from either leaving quarantine if they are negative, or delaying critical care and infecting others if they are positive.
On a societal level, this current testing scheme yields incomplete surveillance data on which
response efforts such as societal reopening and hospital management depend. Though qRT-PCR
is considered the gold-standard diagnostic method because of its high sensitivity and specificity,
the logistical hurdles render it unrealistic for large-scale screening.

372 As qRT-PCR remains impractical for this strategy, and rapid tests are facing regulatory 373 challenges because they do not perform with qRT-PCR-like accuracy, rapid test screening is either 374 nonexistent in several countries or symptom-based. Even under best-case assumptions, findings 375 have shown that symptom and risk-based screening strategies miss more than half of the infected 376 individuals (42). Some have argued that the need for widespread testing is overstated due to the 377 variability in test sensitivity and specificity (43). Here, we present alternative large-scale 378 diagnostic tools to qRT-PCR, and show that test performance, though valuable, is secondary to 379 widespread test frequency, which is enabled by accessibility and turnaround time. Furthermore, 380 test affordability is essential for the successful implementation in communities most affected by 381 infection and will to speed up the safe opening and functioning of the viral sectors of the economy. 382 Giordano et al. has modeled the evolution of SARS-CoV-2 spread, introducing a diagnosed 383 state to elucidate the importance of population-wide testing (17). Mina et al. has examined how 384 various test sensitivities and frequencies affect the reproductive number (12). We build upon these 385 findings to show how in affected United States and Brazil regions, population-wide frequent and 386 rapid testing schemes, with sensitivities ranging from 30%-90%, can be more effective in curbing 387 the pandemic than a PCR-based scheme. Integrating real-world surveillance and clinical data into 388 our modeling system has allowed us to incorporate regional differences - such as variances in 389 healthcare access, state health policy and adherence, state GDP, and environmental factors - under the same model. Significantly, our findings hold true across Massachusetts, New York City, Los Angeles, and São José do Rio Preto, Brazil. We also present the economic considerations of these testing regimes, showing that widespread rapid testing is more cost efficient than less frequent qRT-PCR testing. In line with these economic considerations, our model demonstrates the effectiveness of a geographic-based frequent testing regime, in which high disease prevalence areas receive more frequent testing than low disease prevalence areas.

396 Since COVID-19 is known to affect certain demographics differently, modeling would 397 benefit from incorporating demographic information correlated with disease progression and 398 spread to define sub-models and sets of parameters accordingly. Age, pre-existing conditions, job 399 types, and density of population are examples of possible categories, each of which influence the 400 risk of contracting and/or dying from COVID-19. Further studies would benefit from incorporating 401 these ideas to better understand the effectiveness of rapid testing on identifying potential super 402 spreading events. Future public health prevention programs should use the proposed modeling 403 system to develop and test scenarios for precision testing and prevention.

404 Our findings also point to low-cost tools for implementation of this testing strategy, such 405 as a rapid antigen-based test for the detection of SARS-CoV-2 proteins. We show that the rapid 406 antigen tests perform with a range of accuracies under which disease spread can be dramatically 407 mitigated under our model. Notably, the sensitivity is correlated to the individual's viral load, 408 effectively diagnosing those who are potentially the most infectious with the highest accuracy. Our 409 findings are significant because rapid antigen tests are cheaper than qRT-PCR, can be mass 410 produced to millions per day, present results within 15 minutes, and can be administered by a 411 nonexpert without a lab or special equipment.

412 There are several policy implications for these findings. First, our model supports that 413 systems of high frequency rapid testing should be implemented as a first-line screening method. 414 This can be first enabled by a more holistic regulatory evaluation of rapid diagnostics, such that 415 policy emphasizes accessibility and turnaround time even under a range of accuracies. One can 416 imagine a less accurate, though rapid method of first-line screening in schools, public 417 transportation, and airports, or even at home, and a qRT-PCR-based method for second-line 418 screening (testing those who present severe symptoms or have been in contact with infected 419 individuals, testing in a clinical setting, etc). Second, our cost analysis and rapid antigen test data 420 present a viable and potentially more cost-effective method for screening. Third, our county-based 421 testing scheme presents a possible method for wide-scale screening while optimizing resources. 422 Future studies should investigate how this selective testing strategy can be applied to different 423 location scales to further inform health policy. Moreover, though our models analyze regions in 424 the United States and Brazil, similar testing strategies can be considered globally in both resource 425 limited and abundant settings due to the higher accessibility of rapid tests compared to qRT-PCR. 426 We emphasize that integral to the effectiveness of diagnostic schemes is 1) the proper 427 adherence to quarantine measures and 2) the combined use of a variety of diagnostic methods 428 including nucleic acid, antigen, and antibody tests. According to these models, rapid antigen tests 429 are an ideal tool for first-line screening. Clinical molecular tests such as qRT-PCR are vital to the 430 diagnostic landscape, particularly to re-test suspected cases that were negative on the rapid test. 431 Because rapid tests present a higher rate of false negatives, methods such as qRT-PCR remain 432 integral to second-line screening. Antibody tests provide important information for immunity and 434 individuals will quarantine themselves before being tested and for 14 days following a positive435 diagnostic result.

436 Our simulations combined with real-world data demonstrate a robust modeling system and 437 elucidates the significance of this novel testing strategy. However, there are important limitations 438 to be considered. Differences in disease reporting between the geographical regions and the 439 incomplete nature of COVID-19 surveillance data, often due to the lack of testing, are not 440 considered in the model. It is imperative that the testing results, hospitalization and death statistics, 441 and changes in protocol are reported in real-time to scientists and policy makers so that models 442 can be accurately tuned as the pandemic develops. The model also does not take into account 443 infrastructural limitations such as hospital capacity. Though the rapid antigen test offers several 444 advantages such as affordability, fast turnaround time, and ease of mass production, we are also 445 assuming that there are systems in place to implement frequent and safe low-cost screening across 446 different communities and settings.

Our model underscores the need for a point-of-care or at-home test for frequent screening, particularly as lockdown restrictions ease. Regulatory agencies such as the FDA could work towards regulating rapid tests to alternative standards other than comparison to high sensitivity molecular diagnostics, as our model shows that frequency and scale of testing may overcome lower sensitivities. Rather, we could refocus policy to implement first-line screening that optimizes accuracy with efficiency and equitability.

- 453
- 454
- 455
- 456

457 MATERIAL AND METHODS

458 Development of Direct Antigen Rapid Tests for the Detection of SARS-CoV-2

459 We developed a direct antigen rapid test for the detection of the nucleocapsid protein or 460 spike glycoprotein from SARS-CoV-2 in nasal or nasopharyngeal swab specimens as previously 461 described (44). Briefly, the rapid antigen tests are immunochromatographic format with a visual 462 readout using anti-N or anti-S mouse monoclonal antibodies (E25Bio, Inc., Cambridge, MA, USA) 463 that are either coupled to 40 nm gold nanoparticles (Abcam, Cambridge, UK) or adsorbed to 464 nitrocellulose membranes (Sartorius, Goettingen, Germany). Each rapid antigen test has a control 465 area adjacent to the paper absorbent pad; the control is an anti-mouse Fc domain antibody (Leinco 466 Technologies, Fenton, MO, USA) that will capture any of the antibody-conjugated gold 467 nanoparticles to generate a control visual signal. A visual signal at the test area reflects SARS-468 CoV-2 N or S that is "sandwiched" between an anti-N or anti-S antibody adsorbed to the 469 nitrocellulose membrane and a second anti-N or anti-S antibody covalently coupled to visible gold 470 nanoparticles.

471

472 Validation of Direct Antigen Rapid Test for the Detection of SARS-CoV-2

In a retrospective study of nasal swab specimens form human patients, we compared the accuracy of the rapid antigen test for detection of SARS-CoV-2 N to the viral loads of individuals. Nasal swab specimens (n=190) were tested following approved human subjects use protocols. The nasal swab specimens were banked frozen from suspected patients submitted to PATH for routine COVID diagnosis. Prior to using the rapid test, the nasal swab specimens were validated by qRT-PCR using the FDA EUA ThermoFisher/AppliedBiosystems TaqPATH COVID-19 Combo Kit (ThermoFisher, Waltham, MA USA). The primary study under which the samples and data were collected received ethical clearance from the PATH Research Ethics Committee, protocol number
00004244. The nasal swab specimens were de-identified, containing no demographic data, prior
to analysis.

The nasal swabs were originally collected in 1 mL PBS, where 50 µl was mixed with 50 µl of Solution Buffer (0.9% NaCl and 0.1% Triton X-100). The 100 µl mixture was then pipetted onto the rapid antigen test for SARS-CoV-2 nucleocapsid detection and allowed to react for 15 minutes. After processing of the rapid antigen test, the visual positive or negative signal was documented.

488 Additionally, in a retrospective study of nasopharyngeal swab specimens from human 489 patients, we compared the accuracy of the rapid antigen test to the viral load of individuals. 490 Nasopharyngeal swab specimens (n = 121) were tested in Brazil following approved human 491 subjects use protocols. The age of study participants ranged from 1 to 95 years with an overall 492 median of 37 years (interquartile range, 27–51 years), and 62% were female. The demographic 493 summary of the patients are included in Table S3. The nasopharyngeal swab specimens were 494 banked refrigerated or frozen samples from suspected patients submitted to the lab for routine COVID diagnosis. Prior to using the rapid test, the nasopharyngeal swab samples were validated 495 by qRT-PCR using GeneFinderTM COVID-19 Plus RealAmp Kit (OSANGHealtcare, Anyang-si, 496 497 Gyeonggi-do, Republic of Korea I). The primary study under which the samples and data were 498 collected received ethical clearance from the Faculdade de Medicina de São José do Rio Preto 499 (FAMERP), protocol number 31588920.0.0000.5415. All excess samples and corresponding data 500 were banked and de-identified prior to the analyses.

501 Nasopharyngeal swab specimens (1 mL) were concentrated using Vivaspin 500 centrifugal
 502 concentrator (Sartorius, Goettingen, Germany) at 12,000 x g for 10 minutes. The concentrated

nasopharyngeal swab specimen retentate was transferred to a collection tube and the rapid antigen test for SARS-CoV-2 spike detection was inserted into the tube with the retentate and allowed to react for 15 minutes. After processing of the rapid antigen test, the visual positive or negative signal was documented.

507

508 Data for Modeling

509 As of August 2020, the United States and Brazil have the highest number of confirmed 510 COVID-19 cases and deaths worldwide, with both countries reporting their first case on 26 511 February 202) (1). Although several affected US regions could have been modeled, we look at 512 data from Massachusetts, New York, and Los Angeles: these regions each contained "hotspots", 513 or areas of surging COVID-19 cases, at different points in time during the pandemic and have 514 publicly available government-provided surveillance data. Our model is fit using data over 105 515 days beginning on April 1 for Figure 2 and 105 days beginning on April 10 for Figure 3 (see 516 "Modeling Parameters" in Methods). In order to understand the various testing proposals on a 517 global scale, we performed our clinical study in and expanded the modeling study to Brazil. The 518 specific data we use to fit our model are cumulative confirmed cases, total deaths, and number of 519 daily hospitalizations due to COVID-19. This surveillance data was retrieved from government-520 provided online databases (45–51).

521

522 Modeling Parameters

523 Equation 2 below provides the exact differential equations governing the model.

$\mathrm{d}\mathbf{S} =$	$-\mathbf{S}\left(lpha\mathbf{I}+\eta\mathbf{D}+\gamma ight)$	$+\psi \mathbf{Q_U}$
$\mathrm{d}\mathbf{I} =$	$-\mathbf{I}\left(\varepsilon+\lambda+ u ight)$	$+\mathbf{S}\left(\alpha\mathbf{I}+\eta\mathbf{D}\right)$
$\mathrm{d}\mathbf{D} =$	$- \mathbf{D} \left(rac{\mathbf{D} + \mathbf{I}}{\mathbf{D}} \mu + ho ight)$	$+ \mathbf{I}(u + arepsilon)$
$\mathrm{d}\mathbf{H} =$	$-\mathbf{H}\left(\sigma+ au ight)$	$+ \mu \left(\mathbf{D} + \mathbf{I} \right)$
$\mathrm{d}\mathbf{E} =$		$+ au \mathbf{H}$
$\mathrm{d}\mathbf{R} =$	$-\gamma \mathbf{R}$	$+ \rho \mathbf{D} + \lambda \mathbf{I} + \sigma \mathbf{H} + \psi \mathbf{Q_R}$
$\mathrm{d}\mathbf{Q}_{\mathbf{U}} =$	$-\psi {f Q}_{f U}$	$+ \gamma S$
$\mathrm{d}\mathbf{Q}_{\mathbf{R}} =$	$-\psi \mathbf{Q_R}$	$+ \gamma \mathbf{R}$
		(2)

524

In order to determine the values of the parameters defining the flows between states, we use a least 525 526 squares regression performed at seven day intervals in the datasets to which we fit. This allows 527 the model to take into account the time dependent nature of the parameters, which rely on factors 528 such as social distancing regulations and changes in testing capacity. We also fit window sizes 529 between 1 and 21 days and find that while the fit degrades with larger window size, the overall 530 shape of the fits do not change. We choose seven days assuming policy changes take a week to 531 become effective and that reasonable parameters can be expected to change within this time period. 532 Also, the seven day window size accounts for the fact that often data is not reported as diligently 533 over the weekend. Time series of the values of the parameters for the geographic locations 534 discussed in this paper are included in Figure S5.

Given the restrictions on data available for the populations of various states, varying all of the parameters results in an over parameterized system. Therefore, a subset of the model parameters are fit while the others are either extracted from other sources; see Table 3. The fitting procedure minimizes the sum of the squared residuals of the total cases, current daily hospitalizations, cumulative deaths, and percentage of total infected individuals currently hospitalized. The first three are present in the data sets while the latter is derived from the estimates of the ratio between infected undetected to infected detected individuals from the CDC Laboratory 542 Seroprevalence Survey Data (*52*). While this ratio changes over time, the percentage of infected 543 individuals developing severe symptoms should remain roughly constant throughout the course of 544 the epidemic in the different locations studied.

We consider the data sets for outbreaks in MA, NYC, LA, and SJRP, Brazil (45–50). While each location has testing and fatality information dating back to January, hospitalization data was not included until late March (for NYC and SJRP) and April (for MA and LA). Hence we begin our fitting procedure and testing strategy on 1 April for each of the data sets; by this point, the outbreak is advanced in NYC, substantial in MA, non-negligible, but far from its peak, in LA, and in early stages in SJRP, Brazil. Starting simulations at various stages of the outbreak allows one to see the difference in results between when a testing strategy is administered.

552 In order to determine the effectiveness of the county-based strategy when applied to the 553 state of California, we also fit all of the counties in California with a population greater than 1.5% 554 of that of the entire state and with greater than zero deaths. The results do not depend on these 555 selections, but instead suggest a practical criteria to administer limited resources. The fitting is 556 done starting 10 April for these counties, as at this point the outbreak is sufficiently well-557 documented in each to successfully model. For the county-level data we compute a seven day 558 running average of each of the data sets to which we then fit in order to smooth out fluctuations in 559 the data, likely due to reporting, which are more significant here than in the other data sets 560 considered, as the county populations are smaller and hence discrepancies impact the smoothness 561 of the data more. The fits for each of the counties can be found in Figure S6.

As one can see from Figure 1, these data sets are particularly not smooth, which indicates inefficiencies in reporting. Additionally, it is difficult to gauge their consistency within the dates provided or to compare between locations, as reporting mechanisms changed over time within the

565	same locations. Despite this lack of consistency, our model and fitting mechanism was successful
566	in reproducing the progress of the outbreak in each data set studied.
567	The authors confirm that the data supporting the findings of this study are available within the
568	article and/or its supplementary materials; any other data will be made available upon request. Our
569	code can be found on github: <u>https://github.com/badeaa3/COVID19_Rapid_Testing</u> . The code is
570	written using python with the packages scipy, numpy, lmfit, matplotlib and plotly (53–57).
571	Supplementary Materials
572	
573	Table S1. Data summary of direct antigen rapid test (DART) for detection of SARS-CoV-2
574	nucleocapsid protein and DART for detection of SARS-CoV-2 spike glycoprotein
575	performance in comparison to qRT-PCR results.
576	
577	Table S2. Summary of results of COVID-19 outcomes in 3 US Regions and Brazil as a result
578	of Frequent Rapid Testing Protocol using SIDHRE-Q Model.
579	
580	Table S3. Demographic and clinical summary of patients evaluated by the SARS-CoV-2
581	Direct Antigen Rapid Test (DART).
582	
583	Figure S1. Performance of direct antigen rapid test (DART) for the detection of SARS-
584	CoV-2 (A) nuceleocapsid protein and (B) spike glycoprotein. Shown are the percentile

585 positive cases of the total positive population conditioned to qRT-PCR Cycle Threshold (Ct).

Percentile Positive ranks the samples in order of high Ct to low Ct. DART sensitivity is
determined by calculating true positive agreement to qRT-PCR; the plot uses an ax^b+c fit and
95% confidence intervals for the sensitivity.

589

590 Figure S2. Graphical scheme displaying the relationships between the stages of quarantine

and infection in *SIDHRE-Q* model: Q-U, quarantine uninfected; S, susceptible (uninfected); I,
infected undetected (pre-testing and infected); D, infected detected (infection diagnosis through
testing); H, hospitalized (infected with life threatening symptom progression); R, recovered
(healed); E, extinct (dead); and Q-R, quarantine recovered (healed but in quarantine by false

595 positive testing).

596

597 Figure S3. COVID-19 Outcomes as a result of Frequent Rapid Testing Protocol with 598 variable test performances using SIDHRE-Q Model. The Cumulative Detected Infected, 599 Hospitalized, Deceased, Active Infections, Recovered, and Quarantined are modeled over 105 600 days (top to bottom) using reported data from 4 global regions: Massachusetts, Los Angeles, 601 New York City, and São José do Rio Preto in Brazil (left to right). The COVID-19 population 602 spread and outcomes are modeled under a Rapid Testing Protocol with variable testing 603 frequencies ranging from 1-21 days between tests, and variable test performances: 90% 604 specificity with 90% sensitivity (A), 70% sensitivity (B), 50% sensitivity (C), and 30% 605 sensitivity (D); and 80% specificity with 90% sensitivity (E), 70% sensitivity (F), 50% 606 sensitivity (G), and 30% sensitivity (H). This protocol is compared to a symptom-based Rapid 607 Testing protocol and a symptom-based qRT-PCR protocol.

608

609	Figure S4. Effect of Rapid Testing Protocol under variable testing sensitivities and
610	increasing frequency under the SIDHRE-Q Model. The Cumulative Infections, Maximum
611	Simultaneously Hospitalized, and Deceased populations are modeled for Massachusetts, Los
612	Angeles, New York City, and São José do Rio Preto in Brazil. The effect of increasing frequency
613	of testing is modeled for various testing sensitivities (30%-90%) with an 80% specificity.
614	
615	
616	Figure S5. Time series of the four fitted parameters α , ν , μ , and τ (left to right) for MA, LA,
617	NYC, and SJRP (top to bottom). See Table 2 in the Methods section for an explanation of the
618	parameters. The values are extracted every seven days from data provided by the respective
619	regions. The parameters vary significantly over time and location. Flat points occur during the
620	seven day windows where the parameters are held constant. The fitting procedure is also outlined
621	in the Methods section.
622	
623	Figure S6. Time series of the three fitted pieces of data Cumulative Cases, Daily
624	Hospitalized, and Cumulative Deaths (left to right) for each county receiving testing in CA;
625	Ventura (2A), Stanislaus (2B), Santa Clara (2C), San Joaquin (2D), San Francisco (2E), San
626	Diego (2F), San Bernardino (2G), Sacramento (2H), Orange (2I), Los Angeles (2J), Kern (2K),
627	Fresno (2L), Alameda (2M). The counties included satisfy two requirements: population greater
628	than 1.5% of the total CA population and nonzero total number of deaths at each point in time.
629	The fitting procedure is outlined in the Methods section.

63	51

632	References	
633	1. C	Coronavirus Disease (COVID-19) Situation Reports, (available at
634	h	ttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports).
635	2. T	T. F. Menkir, T. Chin, J. A. Hay, E. Surface, P. Martinez de Salazar, C. Buckee, M. J. Mina,
636	K	K. Khan, A. Watts, M. Lipsitch, R. Niehus, Estimating the number of undetected COVID-19
637	c	ases exported internationally from all of China. medRxiv (2020),
638	d	loi:10.1101/2020.03.23.20038331.
639	3. B	3. Ivorra, M. R. Ferrández, M. Vela-Pérez, A. M. Ramos, Mathematical modeling of the
640	sj	pread of the coronavirus disease 2019 (COVID-19) taking into account the undetected
641	ir	nfections. The case of China. Commun Nonlinear Sci Numer Simul, 105303 (2020).
642	4. N	A. Salathé, C. L. Althaus, R. Neher, S. Stringhini, E. Hodcroft, J. Fellay, M. Zwahlen, G.
643	S	enti, M. Battegay, A. Wilder-Smith, I. Eckerle, M. Egger, N. Low, COVID-19 epidemic in
644	S	witzerland: on the importance of testing, contact tracing and isolation. Swiss Med Wkly.
645	1	50 , w20225 (2020).
646	5. H	I. Lau, T. Khosrawipour, P. Kocbach, H. Ichii, J. Bania, V. Khosrawipour, Evaluating the

- 647 massive underreporting and undertesting of COVID-19 cases in multiple global epicenters.
- *Pulmonology* (2020), doi:10.1016/j.pulmoe.2020.05.015.

649	6.	J. D. Silverman, N. Hupert, A. D. Washburne, Using influenza surveillance networks to
650		estimate state-specific prevalence of SARS-CoV-2 in the United States. Science
651		Translational Medicine (2020), doi:10.1126/scitranslmed.abc1126.
652	7.	D. Böhning, I. Rocchetti, A. Maruotti, H. Holling, Estimating the undetected infections in the
653		Covid-19 outbreak by harnessing capture-recapture methods. Int. J. Infect. Dis. 97, 197-201
654		(2020).
655	8.	Y. H. Baek, J. Um, K. J. C. Antigua, JH. Park, Y. Kim, S. Oh, Y. Kim, WS. Choi, S. G.
656		Kim, J. H. Jeong, B. S. Chin, H. D. G. Nicolas, JY. Ahn, K. S. Shin, Y. K. Choi, JS. Park,
657		MS. Song, Development of a reverse transcription-loop-mediated isothermal amplification
658		as a rapid early-detection method for novel SARS-CoV-2. Emerg Microbes Infect. 9, 998-
659		1007 (2020).
660	9.	L. Leo, Mylab gets commercial approval from ICMR for Covid-19 antigen rapid testing kit.
661		Livemint (2020), (available at https://www.livemint.com/news/india/mylab-gets-commercial-
662		approval-from-icmr-for-covid-19-antigen-rapid-testing-kit-11595434040321.html).
663	10.	S. Dey, Coronavirus testing: Rapid antigen tests now make up nearly half of daily checks
664		India News - Times of India. The Times of India, (available at
665		https://timesofindia.indiatimes.com/india/rapid-antigen-tests-now-make-up-nearly-half-of-
666		daily-checks/articleshow/77340459.cms).
667	11.	C. B. F. Vogels, A. F. Brito, A. L. Wyllie, J. R. Fauver, I. M. Ott, C. C. Kalinich, M. E.
668		Petrone, A. Casanovas-Massana, M. Catherine Muenker, A. J. Moore, J. Klein, P. Lu, A. Lu-
669		Culligan, X. Jiang, D. J. Kim, E. Kudo, T. Mao, M. Moriyama, J. E. Oh, A. Park, J. Silva, E.

- 670 Song, T. Takahashi, M. Taura, M. Tokuyama, A. Venkataraman, O.-E. Weizman, P. Wong,
- 671 Y. Yang, N. R. Cheemarla, E. B. White, S. Lapidus, R. Earnest, B. Geng, P. Vijayakumar, C.
- 672 Odio, J. Fournier, S. Bermejo, S. Farhadian, C. S. Dela Cruz, A. Iwasaki, A. I. Ko, M. L.
- 673 Landry, E. F. Foxman, N. D. Grubaugh, Analytical sensitivity and efficiency comparisons of
- 674 SARS-CoV-2 RT-qPCR primer-probe sets. *Nat Microbiol* (2020), doi:10.1038/s41564-020-
- **675** 0761-6.
- 12. D. B. Larremore, B. Wilder, E. Lester, S. Shehata, J. M. Burke, J. A. Hay, M. Tambe, M. J.
- 677 Mina, R. Parker, Test sensitivity is secondary to frequency and turnaround time for COVID-
- 678 19 surveillance. *medRxiv* (2020), doi:10.1101/2020.06.22.20136309.
- 679 13. Z. Shen, F. Ning, W. Zhou, X. He, C. Lin, D. P. Chin, Z. Zhu, A. Schuchat, Superspreading
 680 SARS events, Beijing, 2003. *Emerging Infect. Dis.* 10, 256–260 (2004).
- 681 14. J. S. M. Peiris, C. M. Chu, V. C. C. Cheng, K. S. Chan, I. F. N. Hung, L. L. M. Poon, K. I.
- 682 Law, B. S. F. Tang, T. Y. W. Hon, C. S. Chan, K. H. Chan, J. S. C. Ng, B. J. Zheng, W. L.
- 683 Ng, R. W. M. Lai, Y. Guan, K. Y. Yuen, HKU/UCH SARS Study Group, Clinical
- 684 progression and viral load in a community outbreak of coronavirus-associated SARS
- 685 pneumonia: a prospective study. *Lancet.* **361**, 1767–1772 (2003).
- 686 15. X. He, E. H. Y. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. Guan, X.
- 687 Tan, X. Mo, Y. Chen, B. Liao, W. Chen, F. Hu, Q. Zhang, M. Zhong, Y. Wu, L. Zhao, F.
- 688 Zhang, B. J. Cowling, F. Li, G. M. Leung, Temporal dynamics in viral shedding and
- 689 transmissibility of COVID-19. *Nat. Med.* **26**, 672–675 (2020).

690	16. J. Bullard, K. Dust, D. Funk, J. E. Strong, D. Alexander, L. Garnett, C. Boodman, A. Bello,
691	A. Hedley, Z. Schiffman, K. Doan, N. Bastien, Y. Li, P. G. Van Caeseele, G. Poliquin,
692	Predicting infectious SARS-CoV-2 from diagnostic samples. Clin. Infect. Dis. (2020),
693	doi:10.1093/cid/ciaa638.
694	17. G. Giordano, F. Blanchini, R. Bruno, P. Colaneri, A. Di Filippo, A. Di Matteo, M. Colaneri,

Modelling the COVID-19 epidemic and implementation of population-wide interventions in
Italy. *Nat. Med.* 26, 855–860 (2020).

- 697 18. S. Choi, M. Ki, Estimating the reproductive number and the outbreak size of COVID-19 in
 698 Korea. *Epidemiol Health.* 42, e2020011 (2020).
- 699 19. Y. Y. Wei, Z. Z. Lu, Z. C. Du, Z. J. Zhang, Y. Zhao, S. P. Shen, B. Wang, Y. T. Hao, F.

Chen, [Fitting and forecasting the trend of COVID-19 by SEIR(+CAQ) dynamic model]. *Zhonghua Liu Xing Bing Xue Za Zhi.* 41, 470–475 (2020).

- 702 20. Z. Yang, Z. Zeng, K. Wang, S.-S. Wong, W. Liang, M. Zanin, P. Liu, X. Cao, Z. Gao, Z.
- 703 Mai, J. Liang, X. Liu, S. Li, Y. Li, F. Ye, W. Guan, Y. Yang, F. Li, S. Luo, Y. Xie, B. Liu,
- Z. Wang, S. Zhang, Y. Wang, N. Zhong, J. He, Modified SEIR and AI prediction of the
- epidemics trend of COVID-19 in China under public health interventions. *J Thorac Dis.* 12, 165–174 (2020).
- 21. S. Cao, P. Feng, P. Shi, [Study on the epidemic development of COVID-19 in Hubei
- province by a modified SEIR model]. *Zhejiang Da Xue Xue Bao Yi Xue Ban.* 49, 178–184
 (2020).

710	22. R. Huang, M. Liu, Y. Ding, Spatial-temporal distribution of COVID-19 in China and its
711	prediction: A data-driven modeling analysis. J Infect Dev Ctries. 14, 246–253 (2020).
712	23. A. Godio, F. Pace, A. Vergnano, SEIR Modeling of the Italian Epidemic of SARS-CoV-2
713	Using Computational Swarm Intelligence. Int J Environ Res Public Health. 17 (2020),
714	doi:10.3390/ijerph17103535.
715	24. M. Gatto, E. Bertuzzo, L. Mari, S. Miccoli, L. Carraro, R. Casagrandi, A. Rinaldo, Spread
716	and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment
717	measures. Proc. Natl. Acad. Sci. U.S.A. 117, 10484–10491 (2020).
718	25. C. Hou, J. Chen, Y. Zhou, L. Hua, J. Yuan, S. He, Y. Guo, S. Zhang, Q. Jia, C. Zhao, J.
719	Zhang, G. Xu, E. Jia, The effectiveness of quarantine of Wuhan city against the Corona
720	Virus Disease 2019 (COVID-19): A well-mixed SEIR model analysis. J. Med. Virol. 92,
721	841–848 (2020).
722	26. T. Zhou, Q. Liu, Z. Yang, J. Liao, K. Yang, W. Bai, X. Lu, W. Zhang, Preliminary prediction
723	of the basic reproduction number of the Wuhan novel coronavirus 2019-nCoV. J Evid Based
724	<i>Med.</i> 13 , 3–7 (2020).

- 725 27. C. Reno, J. Lenzi, A. Navarra, E. Barelli, D. Gori, A. Lanza, R. Valentini, B. Tang, M. P.
- 726 Fantini, Forecasting COVID-19-Associated Hospitalizations under Different Levels of
- 727 Social Distancing in Lombardy and Emilia-Romagna, Northern Italy: Results from an
- Extended SEIR Compartmental Model. J Clin Med. 9 (2020), doi:10.3390/jcm9051492.

729	28. F. Yu, L. Yan, N. Wang, S. Yang, L. Wang, Y. Tang, G. Gao, S. Wang, C. Ma, R. Xie, F	7.
730	Wang, C. Tan, L. Zhu, Y. Guo, F. Zhang, Quantitative Detection and Viral Load Analyst	is of
731	SARS-CoV-2 in Infected Patients. Clin. Infect. Dis. 71, 793-798 (2020).	
732	29. S. N. Rao, D. Manissero, V. R. Steele, J. Pareja, A Narrative Systematic Review of the	
733	Clinical Utility of Cycle Threshold Values in the Context of COVID-19. Infect Dis There	1–
734	14 (2020).	
735	30. J. Alizargar, Risk of reactivation or reinfection of novel coronavirus (COVID-19). J.	
736	Formos. Med. Assoc. 119, 1123 (2020).	
737	31. D. Batisse, N. Benech, E. Botelho-Nevers, K. Bouiller, R. Collarino, A. Conrad, L. Galla	ıy,
738	F. Goehringer, M. Gousseff, D. C. Joseph, A. Lemaignen, FX. Lescure, B. Levy, M.	
739	Mahevas, P. Penot, B. Pozzetto, D. Salmon, D. Slama, N. Vignier, B. Wyplosz, Clinical	
740	recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or	
741	inflammatory rebound? J. Infect. (2020), doi:10.1016/j.jinf.2020.06.073.	
742	32. W. Deng, L. Bao, J. Liu, C. Xiao, J. Liu, J. Xue, Q. Lv, F. Qi, H. Gao, P. Yu, Y. Xu, Y. C.	Qu,
743	F. Li, Z. Xiang, H. Yu, S. Gong, M. Liu, G. Wang, S. Wang, Z. Song, Y. Liu, W. Zhao, Y	Y.
744	Han, L. Zhao, X. Liu, Q. Wei, C. Qin, Primary exposure to SARS-CoV-2 protects against	st
745	reinfection in rhesus macaques. Science (2020), doi:10.1126/science.abc5343.	
746	33. M. Ota, Will we see protection or reinfection in COVID-19? Nat. Rev. Immunol. 20, 351	
747	(2020).	

748	34. A. Victor Okhuese, Estimation of the Probability of Reinfection With COVID-19 by the
749	Susceptible-Exposed-Infectious-Removed-Undetectable-Susceptible Model. JMIR Public
750	<i>Health Surveill.</i> 6 , e19097 (2020).
751	35. Y. Gu, COVID-19 Projections Using Machine Learning. COVID-19 Projections Using
752	Machine Learning, (available at https://covid19-projections.com/).
753	36. D. Stadlbauer, J. Tan, K. Jiang, M. Hernandez, S. Fabre, F. Amanat, C. Teo, G. A.
754	Arunkumar, M. McMahon, J. Jhang, M. Nowak, V. Simon, E. Sordillo, H. van Bakel, F.
755	Krammer, <i>medRxiv</i> , in press, doi:10.1101/2020.06.28.20142190.
756	37. A. Goodnough, M. D. Shear, The U.S.'s Slow Start to Coronavirus Testing: A Timeline. The
757	New York Times (2020), (available at https://www.nytimes.com/2020/03/28/us/coronavirus-
758	testing-timeline.html).
759	38. M. D. Shear, A. Goodnough, S. Kaplan, S. Fink, K. Thomas, N. Weiland, The Lost Month:
760	How a Failure to Test Blinded the U.S. to Covid-19. The New York Times (2020), (available
761	at https://www.nytimes.com/2020/03/28/us/testing-coronavirus-pandemic.html).
762	39. S. Kaplan, K. Thomas, Despite Promises, Testing Delays Leave Americans 'Flying Blind.'
763	The New York Times (2020), (available at
764	https://www.nytimes.com/2020/04/06/health/coronavirus-testing-us.html).
765	40. W. M. de Souza, L. F. Buss, D. da S. Candido, JP. Carrera, S. Li, A. E. Zarebski, R. H. M.
766	Pereira, C. A. Prete, A. A. de Souza-Santos, K. V. Parag, M. C. T. D. Belotti, M. F.

- 767 Vincenti-Gonzalez, J. Messina, F. C. da Silva Sales, P. dos S. Andrade, V. H. Nascimento, F.
- 768 Ghilardi, L. Abade, B. Gutierrez, M. U. G. Kraemer, C. K. V. Braga, R. S. Aguiar, N.

769	Alexander, P. Mayaud, O. J. Brady, I. Marcilio, N. Gouveia, G. Li, A. Tami, S. B. de
770	Oliveira, V. B. G. Porto, F. Ganem, W. A. F. de Almeida, F. F. S. T. Fantinato, E. M.
771	Macário, W. K. de Oliveira, M. L. Nogueira, O. G. Pybus, CH. Wu, J. Croda, E. C. Sabino,
772	N. R. Faria, Epidemiological and clinical characteristics of the COVID-19 epidemic in
773	Brazil. Nature Human Behaviour. 4, 856–865 (2020).
774	41. S. Mervosh, M. Fernandez, 'It's Like Having No Testing': Coronavirus Test Results Are
775	Still Delayed. The New York Times (2020), (available at
776	https://www.nytimes.com/2020/08/04/us/virus-testing-delays.html).
777	42. K. Gostic, A. C. Gomez, R. O. Mummah, A. J. Kucharski, J. O. Lloyd-Smith, Estimated
778	effectiveness of symptom and risk screening to prevent the spread of COVID-19. eLife. 9,
779	e55570 (2020).

- 43. T. Zitek, The Appropriate Use of Testing for COVID-19. *West J Emerg Med.* 21, 470–472
 (2020).
- 44. I. Bosch, H. de Puig, M. Hiley, M. Carré-Camps, F. Perdomo-Celis, C. F. Narváez, D. M.
- 783 Salgado, D. Senthoor, M. O'Grady, E. Phillips, A. Durbin, D. Fandos, H. Miyazaki, C.-W.
- Yen, M. Gélvez-Ramírez, R. V. Warke, L. S. Ribeiro, M. M. Teixeira, R. P. Almeida, J. E.
- 785 Muñóz-Medina, J. E. Ludert, M. L. Nogueira, T. E. Colombo, A. C. B. Terzian, P. T. Bozza,
- A. S. Calheiros, Y. R. Vieira, G. Barbosa-Lima, A. Vizzoni, J. Cerbino-Neto, F. A. Bozza, T.
- 787 M. L. Souza, M. R. O. Trugilho, A. M. B. de Filippis, P. C. de Sequeira, E. T. A. Marques,
- 788 T. Magalhaes, F. J. Díaz, B. N. Restrepo, K. Marín, S. Mattar, D. Olson, E. J. Asturias, M.
- 789 Lucera, M. Singla, G. R. Medigeshi, N. de Bosch, J. Tam, J. Gómez-Márquez, C. Clavet, L.

790	Villar, K. Hamad-Schifferli, L. Gehrke, Rapid antigen tests for dengue virus serotypes and
791	Zika virus in patient serum. Sci Transl Med. 9 (2017), doi:10.1126/scitranslmed.aan1589.
792	45. Massachusetts Department of Public Health, COVID-19 Response Reporting. Mass.gov,
793	(available at https://www.mass.gov/info-details/covid-19-response-reporting).
794	46. California Department of Public Health, COVID-19 Cases - California Open Data, (available
795	at https://data.ca.gov/dataset/covid-19-cases).
796	47. California Department of Public Health, COVID-19 Hospital Data - California Open Data,
797	(available at https://data.ca.gov/dataset/covid-19-hospital-data).
798	48. Department of Health and Human Hygiene, COVID-19 Daily Counts of Cases,
799	Hospitalizations, and Deaths NYC Open Data, (available at
800	https://data.cityofnewyork.us/Health/COVID-19-Daily-Counts-of-Cases-Hospitalizations-
801	an/rc75-m7u3).
802	49. Sao Jose do Rio Preto Public Health Office, "COVID-19 Surveillance Data, Sao Jose do Rio
803	Preto" (Sao Jose do Rio Preto Public Health Office, Sao Jose do Rio Preto, Brazil).
804	50. New York State Government, Daily Hospitalization Summary by Region. New York
805	Forward, (available at https://forward.ny.gov/daily-hospitalization-summary-region).
806	51. Massachusetts General Hospital Institute for Technology Assessment, COVID-19 Simulator
807	- Methodology, (available at https://www.covid19sim.org/images/docs/COVID-
808	19_simulator_methodology_download_20200507.pdf).

809	52. CDC, Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention
810	(2020), (available at https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-
811	lab-surveys.html).
812	53. SciPy.org — SciPy.org, (available at https://www.scipy.org/).
813	54. NumPy, (available at https://numpy.org/).
814	55. Non-Linear Least-Squares Minimization and Curve-Fitting for Python — Non-Linear Least-
815	Squares Minimization and Curve-Fitting for Python, (available at
816	https://lmfit.github.io/lmfit-py/).
817	56. Matplotlib: Python plotting — Matplotlib 3.3.1 documentation, (available at
818	https://matplotlib.org/).
819	57. Plotly: The front-end for ML and data science models, (available at https://plotly.com/).
820	
821 822	Acknowledgments
823	General: We thank Professor Lee Gehrke for critical reading of the manuscript.
824	Funding: EN is funded by Tufts University DISC Seed Grant. MLN is supported by a
825	FAPESP grant (#2020/04836-0) and is a CNPq Research Fellow. AFV is supported by a
826	FAPESP Fellow grant (#18/17647-0). GRFC is supported by a FAPESP Fellow grant
827	(#20/07419-0). BHGAM is supported by a FAPESP Scholarship (#19/06572-2). The
828	funders had no role in the design of the study; in the collection, analyses, or interpretation
829	of data; in the writing of the manuscript, or in the decision to publish the results.

830	Author contributions: Conceptualization: BBH. Formal analysis: BN, AB, AR, MB,
831	NS, ARG, AV, GCDS, TMILDS, BHGAM, MMM, GRFC, FQ, AFNR, MLG, ENN, IB,
832	BBH. Funding acquisition: IB, BBH. Investigation: BN, AB, AR, MB, NS, ARG, AV,
833	GCDS, TMILDS, BHGAM, MMM, GRFC, FQ, AFNR, MLG, ENN, IB, BBH.
834	Methodology: BN, AB, AR, MB, NS, ARG, AV, GCDS, TMILDS, BHGAM, MMM,
835	GRFC, FQ, AFNR, MLG, ENN, IB, BBH. Project administration: MLN, IB, BBH.
836	Resources: MLN, IB, BBH. Supervision: MB, MLN, ENN, IB, BBH. Validation: BN,
837	AB, AR, MB, ENN, BBH. Visualization: BN, AB, AR, MB, AV, ENN, BBH. Writing-
838	original draft: AR, BBH. Writing-review and editing: BN, AB, AR, MB, NS, ARG,
839	AV, GCDS, TMILDS, BHGAM, MMM, GRFC, FQ, AFNR, MLG, ENN, IB, BBH.
840	Competing interests: BN, AB, AR, MB, NS, AG, IB, and BBH are employed by or
841	affiliated with E25Bio Inc. (www.e25bio.com), a company that develops diagnostics for
842	epidemic viruses.
843	
844	
845	Figures and Tables
846	
847	TABLES
848	
849	Table 1. Clinical validation summary for the direct antigen rapid test (DART) for SARS-
850	CoV-2 nucleocapsid protein evaluated using 190 retrospectively collected patient nasal
851	swab specimens.
852	

					l Data Su	mmary]
				·PCR verage)					nfidence rval	
			+	-	Total	Sensitivity	80.0%	76.1%	83.9%	
	DART (nucleocapsid protein)	+	80	8	88	Specificity	91.1%	88.2%	94.0%	
	DART (nucleocaps protein)	-	20	82	102	Positive Predictive Value	90.9%	87.9%	93.9%	
		Total	100	90	190	Negative Predictive Value	80.4%	76.6%	84.2%	
						Prevalence	52.6%	47.8%	57.5%	
853						Overall Agreement	85.3%	82.8%	87.8%	
854										
855										
856										
857										
858										
859										
860										
861	Table	2. Clini	cal vali	idation	summ	ary for th	e SARS	S-CoV-2	2 direc	t antigen rapid test
862	(DAR)	Г) for S	ARS-S	oC-2 sj	pike gly	ycoprotein	evalua	ated us	ing 121	retrospectively collected
863	patient	t nasop	haryng	eal swa	ab spec	imens.				
864										
865										

				AI	l Data Su	nmary			
				·PCR verage)					nfidence rval
			+	-	Total	Sensitivity	84.7%	80.6%	88.9%
	(spike rotein)	+	61	7	68	Specificity	85.7%	80.8%	90.6%
	DART (spike glycoprotein)	-	11	42	53	Positive Predictive Value	89.7%	86.2%	93.2%
		Total	72	49	121	Negative Predictive Value	79.2%	73.6%	84.9%
						Prevalence	59.5%	53.9%	65.1%
866						Overall Agreement	85.1%	82.0%	88.3%
867									
868									
869									
870									
871									
872									
873									
874									
875									
876									
877	Table 3	3. Detai	ls of pa	ramete	r value	s used for	SIDHF	<i>RE-Q</i> M	odel.


Parameter	Details & Statistics		
	lpha is the probability that an interaction between an undetected infected person and	Mean	St. Dev.

α	an uninfected person results in a new infection, divided by the average number of uninfected people an undetected infected person comes into contact with on a	МА	0.088	0.051
	given day. α is estimated from the data.	LA	0.090	0.034
		NYC	0.067	0.042
		SJRP	0.121	0.042
η	η is the probability that an interaction between an infected person and an uninfection, divided by the average number of uninfected people a detected infected with on a given day. $\eta = 0.01 \cdot \alpha$ The constant relating η , α accounts for a small but nonzero transmission due to infected population. This value was chosen to be small, assuming a quarantined others with low probability.	d person the qua	comes in rantined	to contact (detected)
ν	v is the probability that a symptomatic undetected individual is diagnosed on a		Mean	St. Dev.
	given day. ν is estimated from the data. ν is multiplied by sensitivity (assume benchmark sensitivity 100% for PCR, as used when fitting).	MA	0.006	0.005
		LA	0.011	0.006
		NYC	0.0056	0.002
		SJRP	0.015	0.007
ϵ				
C	ϵ is the probability that an asymptomatic undetected infected individual is diagnowhile fitting (during PCR symptomatic testing). ϵ =(sensitivity/days between t strategy is activated.			
λ	while fitting (during PCR symptomatic testing). ϵ =(sensitivity/days between t	tests) who	en the rap	oid testing
	while fitting (during PCR symptomatic testing). ϵ =(sensitivity/days between t strategy is activated. λ is the probability that an undetected infected individual transitions to the recovere 1/14, or the inverse of average recovery time (51). μ is the probability that an infected individual develops severe symptoms on a	tests) who	en the rap	oid testing
λ	while fitting (during PCR symptomatic testing). ϵ =(sensitivity/days between t strategy is activated. λ is the probability that an undetected infected individual transitions to the recovere 1/14, or the inverse of average recovery time (51). μ is the probability that an infected individual develops severe symptoms on a given day and transitions into the hospitalized state. The flow from D to H is assumed to be independent of the ratio I/D , but comes only from the detected infected population, hence why it is multiplied by $(I + D)/D$. μ is estimated from	tests) who	n a given o	day. $\lambda =$
λ	while fitting (during PCR symptomatic testing). ϵ =(sensitivity/days between t strategy is activated. λ is the probability that an undetected infected individual transitions to the recovere 1/14, or the inverse of average recovery time (51). μ is the probability that an infected individual develops severe symptoms on a given day and transitions into the hospitalized state. The flow from D to H is assumed to be independent of the ratio I/D , but comes only from the detected	ed state of	n a given o	day. $\lambda =$
λ	while fitting (during PCR symptomatic testing). ϵ =(sensitivity/days between t strategy is activated. λ is the probability that an undetected infected individual transitions to the recovere 1/14, or the inverse of average recovery time (51). μ is the probability that an infected individual develops severe symptoms on a given day and transitions into the hospitalized state. The flow from D to H is assumed to be independent of the ratio I/D , but comes only from the detected infected population, hence why it is multiplied by $(I + D)/D$. μ is estimated from	ed state of MA	Mean 0.0013	day. $\lambda =$ St. Dev. 9.5e-4
λ	while fitting (during PCR symptomatic testing). ϵ =(sensitivity/days between t strategy is activated. λ is the probability that an undetected infected individual transitions to the recovere 1/14, or the inverse of average recovery time (51). μ is the probability that an infected individual develops severe symptoms on a given day and transitions into the hospitalized state. The flow from D to H is assumed to be independent of the ratio I/D , but comes only from the detected infected population, hence why it is multiplied by $(I + D)/D$. μ is estimated from	ed state or MA	Mean 0.0013 0.0016	day. $\lambda =$ St. Dev. 9.5e-4 2.4e-4
λ	while fitting (during PCR symptomatic testing). ϵ =(sensitivity/days between t strategy is activated. λ is the probability that an undetected infected individual transitions to the recovere 1/14, or the inverse of average recovery time (51). μ is the probability that an infected individual develops severe symptoms on a given day and transitions into the hospitalized state. The flow from D to H is assumed to be independent of the ratio I/D , but comes only from the detected infected population, hence why it is multiplied by $(I + D)/D$. μ is estimated from	MA LA NYC SJRP	Mean 0.0013 0.0011 0.0018	id testing day. $\lambda =$ St. Dev. 9.5e-4 2.4e-4 6.6e-4 8.0e-4
μ	while fitting (during PCR symptomatic testing). ϵ =(sensitivity/days between t strategy is activated. λ is the probability that an undetected infected individual transitions to the recovere 1/14, or the inverse of average recovery time (51). μ is the probability that an infected individual develops severe symptoms on a given day and transitions into the hospitalized state. The flow from D to H is assumed to be independent of the ratio I/D , but comes only from the detected infected population, hence why it is multiplied by $(I + D)/D$. μ is estimated from the data.	MA LA NYC SJRP	Mean 0.0013 0.0011 0.0018	id testing day. $\lambda =$ St. Dev. 9.5e-4 2.4e-4 6.6e-4 8.0e-4
μ	while fitting (during PCR symptomatic testing). ϵ =(sensitivity/days between t strategy is activated. λ is the probability that an undetected infected individual transitions to the recovere 1/14, or the inverse of average recovery time (51). μ is the probability that an infected individual develops severe symptoms on a given day and transitions into the hospitalized state. The flow from D to H is assumed to be independent of the ratio I/D , but comes only from the detected infected population, hence why it is multiplied by $(I + D)/D$. μ is estimated from the data. ρ is the probability that a detected infected individual transitions to the recovered s	MA LA NYC SJRP	en the rap n a given of Mean 0.0013 0.0016 0.0018 given day	id testing day. $\lambda =$ St. Dev. 9.5e-4 2.4e-4 6.6e-4 8.0e-4 7.
λ μ ρ	 while fitting (during PCR symptomatic testing). ε =(sensitivity/days between t strategy is activated. λ is the probability that an undetected infected individual transitions to the recoverer 1/14, or the inverse of average recovery time (51). μ is the probability that an infected individual develops severe symptoms on a given day and transitions into the hospitalized state. The flow from D to H is assumed to be independent of the ratio I/D, but comes only from the detected infected population, hence why it is multiplied by (I + D)/D. μ is estimated from the data. ρ is the probability that a detected infected individual transitions to the recovered state. ρ is the probability that a detected infected individual transitions to the recovered state. 	MA LA NYC SJRP	en the rap n a given of Mean 0.0013 0.0016 0.0018 given day	id testing day. $\lambda =$ St. Dev. 9.5e-4 2.4e-4 6.6e-4 8.0e-4 7.


		LA	0.016	0.004
		NYC	0.036	0.034
		SJRP	0.032	0.045
γ	γ is the probability of entering either of the quarantine states on a given day free Recovered populations. $\gamma = 0$ while fitting (during PCR symptomatic testin (1/days between tests) when the rapid testing strategy is activated.			-
ψ	ψ is the probability that an individual exits quarantine on a given day. ψ = quarantine period for fixed length quarantine.	1/14, or	the inver	rse of th
Parameter	Details & Statistics			
	α is the probability that an interaction between an undetected infected person and		Mean	St. Dev.
α 	an uninfected person results in a new infection, divided by the average number of uninfected people an undetected infected person comes into contact with on a given day. Q is estimated from the data.	МА	0.088	0.051
		LA	0.090	0.034
		NYC	0.067	0.042
n	Dis the probability that an interaction between an infected person and an uninfected			
	infection, divided by the average number of uninfected people a detected infected with on a given day $\underline{n} = 0.01 \cdot \alpha$ The constant relating \underline{n}, α accounts for a small but nonzero transmission due to the infected population. This value was chosen to be small, assuming a quarantined in others with low probability.	d person person co	results in omes into	a new contact cted) infect
<u>ח</u>	infection, divided by the average number of uninfected people a detected infected with on a given day $\underline{n} = 0.01 \cdot a$ The constant relating \underline{n}, a accounts for a small but nonzero transmission due to the infected population. This value was chosen to be small, assuming a quarantined in others with low probability. Us the probability that a symptomatic undetected individual is diagnosed on a given day. Us estimated from the data. Us multiplied by sensitivity (assume	ed person person co e quaranti ndividual	results in pomes into aned (detection will only Mean	a new contact cted) infect St. Dev.
	infection, divided by the average number of uninfected people a detected infected with on a given day $\eta = 0.01 \cdot a$ The constant relating η , a accounts for a small but nonzero transmission due to the infected population. This value was chosen to be small, assuming a quarantined in others with low probability.	d person person co	results in omes into ned (detec will only	a new contact cted) infect
	infection, divided by the average number of uninfected people a detected infected with on a given day $\underline{n} = 0.01 \cdot a$ The constant relating \underline{n}, a accounts for a small but nonzero transmission due to the infected population. This value was chosen to be small, assuming a quarantined in others with low probability. Us the probability that a symptomatic undetected individual is diagnosed on a given day. Us estimated from the data. Us multiplied by sensitivity (assume	ed person person co e quaranti ndividual	results in pomes into aned (detection will only Mean	a new contact cted) infect St. Dev.
	infection, divided by the average number of uninfected people a detected infected with on a given day $\underline{n} = 0.01 \cdot a$ The constant relating \underline{n}, a accounts for a small but nonzero transmission due to the infected population. This value was chosen to be small, assuming a quarantined in others with low probability. Us the probability that a symptomatic undetected individual is diagnosed on a given day. Us estimated from the data. Us multiplied by sensitivity (assume	ed person person co e quaranti ndividual MA	results in omes into ned (detection will only Mean 0.006	a new contact cted) infect St. Dev. 0.005
	infection, divided by the average number of uninfected people a detected infected with on a given day $\underline{n} = 0.01 \cdot a$ The constant relating \underline{n}, a accounts for a small but nonzero transmission due to the infected population. This value was chosen to be small, assuming a quarantined in others with low probability. Us the probability that a symptomatic undetected individual is diagnosed on a given day. Us estimated from the data. Us multiplied by sensitivity (assume	ed person person co e quaranti ndividual MA LA	results in omes into ned (deter will only Mean 0.006 0.011	a new contact cted) infect St. Dev. 0.005 0.006
	infection, divided by the average number of uninfected people a detected infected with on a given day $\underline{n} = 0.01 \cdot a$ The constant relating \underline{n}, a accounts for a small but nonzero transmission due to the infected population. This value was chosen to be small, assuming a quarantined in others with low probability. Us the probability that a symptomatic undetected individual is diagnosed on a given day. Us estimated from the data. Us multiplied by sensitivity (assume	ed person person co e quaranti ndividual MA LA NYC SJRP sed on a g	results in omes into omes into omes into omes into will only Mean 0.006 0.011 0.0056 0.015 given day.	a new contact cted) infect st. Dev. 0.005 0.006 0.002 0.007 $\epsilon = 0$
۲	 infection, divided by the average number of uninfected people a detected infected with on a given day. n = 0.01 · a The constant relating n accounts for a small but nonzero transmission due to the infected population. This value was chosen to be small, assuming a quarantined in others with low probability. D is the probability that a symptomatic undetected individual is diagnosed on a given day. Is estimated from the data. Is multiplied by sensitivity (assume benchmark sensitivity 100% for PCR, as used when fitting). I is the probability that an asymptomatic undetected infected individual is diagnosed when fitting (during PCR symptomatic testing). 	ed person person co e quaranti ndividual MA LA NYC SJRP sed on a g	results in omes into one (detective will only Mean 0.006 0.011 0.0056 0.015 given day. the rapid	a new contact cted) infect 3t. Dev. 0.005 0.006 0.002 0.007 $\epsilon = 0$ testing

		given day and transitions into the hospitalized state. The flow from D to \overline{H} is assumed to be independent of the ratio $\overline{I/D}$, but comes only from the detected	МА	0.0013	9.5e-4
		infected population, hence why it is multiplied by $(I + D)/D$. μ is estimated from the data.	LA	0.0016	2.4e-4
			NYC	0.0011	6.6e-4
			SJRP	0.0018	8.0e-4
	ρ	state on a	given day	<i>.</i>	
		$\overline{\rho = 1/14}$, or the inverse of the average recovery time (51).			
	σ	$\overline{\phi}$ is the probability that a hospitalized individual transitions to the recovered state or the inverse of the average recovery time for a hospitalized individual (51).	on a giver	n day. σ	= 1/11,
	τ	\overline{C} is the probability that a hospitalized individual expires on a given day. \overline{C} is		Mean	St. Dev.
		estimated from the data.	MA	0.034	0.012
			LA	0.016	0.004
			NYC	0.036	0.034
			SJRP	0.032	0.045
	Y	$\boxed{\nu}$ is the probability of entering either of the quarantine states on a given day from Recovered populations. $\boxed{\nu = 0}$ while fitting (during PCR symptomatic testing). days between tests $\boxed{\nu}$ when the rapid testing strategy is activated.			
	ψ	$\overline{\psi}$ is the probability that an individual exits quarantine on a given day. $\overline{\psi} = 1/14$ quarantine period for fixed length quarantine.	, or the in	verse of t	he
879					
880					
881					
882					
883	FIGURES				
884					
885	Figure 1. (Graphical scheme displaying the relationships between the s	tages o	f quara	antine
886	and infecti	ion in SIDHRE-Q model. Q-U, quarantine uninfected; S, susce	eptible (uninfe	cted); I,
887	infected un	detected (pre-testing and infected); D , infected detected (infect	ion diag	gnosis t	hrough
		u <i>C), , , </i> (-2		0

- testing); **H**, hospitalized (infected with life threatening symptom progression); **R**, recovered
- (healed); E, extinct (dead); and Q-R, quarantine recovered (healed but in quarantine by false
- 890 positive testing).
- 891




905	spread and outcomes are modeled under a Rapid Testing Protocol (sensitivity 80%, specificity
906	90%) with variable testing frequencies ranging from 1-21 days between tests. This protocol is
907	compared to a symptom-based Rapid Testing protocol and a symptom-based PCR protocol. (B)
908	Effect of Rapid Testing Protocol under variable testing sensitivities (30%-90%) and increasing
909	frequency under the SIDHRE-Q Model. The Cumulative Infections, Maximum Simultaneously
910	Hospitalized, and Deceased populations are modeled for Massachusetts, Los Angeles, New York
911	City, and São José do Rio Preto in Brazil with a 90% test specificity.
912	
913	
914	
915	
916	
917	
918	
919	
920	
921	
922	
923	(A)






(B)



935 Figure 3. Effect of County Based Rapid Testing strategy on COVID-19 outcomes in 936 California. This protocol varies testing frequency in accordance to the number of recorded 937 cases; the threshold for number of active infections which, if reached, signals to commence 938 everyday testing (the highest frequency considered). A Rapid Test with a 80% sensitivity and 939 90% sensitivity versus is used in this deployment strategy. Shown is the total cost per person per 940 day versus the cumulative infections, maximum simultaneously hospitalized, and cumulative 941 deaths with varied thresholds for all of CA is shown. The County Based Rapid Testing strategy 942 is compared to uniform testing, which distributes the same number of total tests used in the 943 county strategy, albeit evenly across each county. The effects of uniform testing are modeled for 944 both a Rapid Testing protocol and a qRT-PCR protocol (A). The effects of County Based Rapid 945 Test Protocol and Uniform PCR Protocol on active infected detected population over time in CA 946 are shown (B). The legend denotes the thresholds at which testing frequency is determined, the 947 testing frequencies, the percent of CA population under the strategy, and the cost per person per day. 948

- 949
- 950
- 951 (A)



953

